August 20, 2017
Did you ever compile a list with the optimal features and desirable properties of a F-18 labeled PSMA inhibitor ?
You would think about:
- high affinity
- excellent biodistribution in man
- unbeatably fast synthesis
- uncomplicated and simple production
- outstanding yields
This short list describes some characteristics of [F-18]rh-PSMA-7.
More information about even more unexpected features oF [F-18]rhPSMA-7 will be published soon.
PLEASE ALSO NOTE ANNOUNCEMENTS OF UPCOMING TRAININGS, WEBINARS AND OTHER EVENTS IN CONNECTION WITH THE INTRODUCTION OF [F-18]rhPSMA-7.
Its Time for Change
Production of our new Ga-68 labeling cassette with significantly improved performance has started. Contact SCINTOMICS for more information.
– lean – intuitive – matured – swift –
The new LIMS system has been developed with GmbH, a provider for laboratory and quality management software with more than 25 years experience in the pharmaceutical industry and health care sector. Together with application specialists of Maqsima, a dedicated and carefully configured solution for radiopharmaceutical laboratories has been developed and filled with a bulk of already installed documents, quality control precudures, specifications and release criteria in consideration of relevant GMP/cGMP guidelines and the monographs of the European Pharmacepeia (9th edition).
See the quality and performance of the FINEO LIMS system its versatile and creative application possibilities for yourself. For more information visit the FINEO product site of directly contact our email application specialist at email@example.com.
2017 Bruno-Allolio Prize of the German Society of Endocrinology awarded to Dr. Carmina Fuß
♦ Congratulation ♦
Dr. Carmina Fuß (Endocrinology & Diabetes Unit, Department of Internal Medicine I, University Hospital of Wuerzburg, GER) will be awared with the 2017 Bruno-Allolio Prize of the German Society of Endocrinology for a study on the diagnosis of aldosterone producing adenoma by means of [Ga-68]Pentixafor PET*.
CXC chemokine receptor type 4 targeted PET imaging for the diagnosis of aldosterone producing adenoma
Heinze1*, C.T. Fuss1*, P. Mulatero2, F. Beuschlein3, M. Reincke3, M. Mustafa4, A. Schirbel5, T. Deutschbein6, T. A. Williams2,3, Y. Rhayem3, M. Quinkler7, N. Rayes8, S. Monticone2, V. Wild9, C. E. Gomez-Sanchez10, A.-C. Reis11, S. Petersenn12, H. J. Wester13, M. Fassnacht1,6, K. Lang1, K. Herrmann5, A. K. Buck5, C. Bluemel5, S. Hahner1
1 Endocrinology & Diabetes Unit, Department of Internal Medicine I, University Hospital of Wuerzburg, University of Wuerzburg, Germany;
2 Division of Internal Medicine and Hypertension, Department of Medical Sciences, University of Torino, Italy;
3 Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Germany,
4 Department of Nuclear Medicine, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany
5 Department of Nuclear Medicine, University Hospital of Wuerzburg, University of Wuerzburg, Germany;
6 Comprehensive Cancer Center Wuerzburg, University Hospital of Wuerzburg, University of Wuerzburg, Germany
7 Endocrinology in Charlottenburg, Berlin, Germany.
8 Department of General, Visceral, and Transplant Surgery, Charité – Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
9 Department of Pathology, University Hospital Würzburg, Germany;
10 Division of Endocrinology, G.V. (Sonny) Montgomery VA Medical Center Mississippi, USA;
11 Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, Germany;
12 ENDOC, Center for Endocrine Tumors, Hamburg, Germany
13 Pharmaceutical Radiochemistry, Technische Universität München , 85748, Garching, Germany
*Pentixafor, SCINTOMICS proprietary CXCR4 targeted radiotracer
We are delighted to start with the exclusive European Distribution (incl. Turkey) of a whole range of prescursors and reference compounds for PET, SPECT and radioligand therapy in R&D and GMP quality.
More information and opening of our comprehensive Chemical and Precursor Database beginning of July.
Priority Partner Program
Current Opening (limited to non-PSMA related topics):
Renowned international sites for first clinical application of selected new F-18, Ga-68 and Lu-177-radiopharmaceuticals. Please contact SCINTOMICS directly.
We support your R&D developments and GMP needs … and create synergies via our unique triple-P initiative.
For over 10 years we are closely interacting with radiopharmacists, researchers and clinical partners to develop custom solutions, innovative imaging and therapy approaches and to translate them into innovative clinical studies. Since we know from our own experience how complicated and time consuming translation into the clinical setting and the routine GMP production with high reliability and efficiency can be, we support our customers in all stages of radiotracer development, from the early CMC stage to the final GMP production.
For dedicated developments and projects of mutual interest, we recently initiated a Priority Partner Program. Give us a call and learn more about the considerable added value of having SCINTOMICS as your highly committed research partner.